Hepatoblastoma – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:16:19 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Hepatoblastoma – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Safety and Effectiveness of Patritumab Deruxtecan for Children with Relapsed or Refractory Hepatoblastoma and Rhabdomyosarcoma https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-patritumab-deruxtecan-for-children-with-relapsed-or-refractory-hepatoblastoma-and-rhabdomyosarcoma/ Wed, 29 Apr 2026 15:05:07 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-patritumab-deruxtecan-for-children-with-relapsed-or-refractory-hepatoblastoma-and-rhabdomyosarcoma/ This clinical trial is focused on studying the effects of a new treatment called patritumab deruxtecan (also known by its code name MK-1022) in children with certain types of cancer. The specific cancers being studied are hepatoblastoma and rhabdomyosarcoma, which are types of solid tumors that have either returned after treatment or have not responded to previous treatments. The purpose of the study is to evaluate the safety and effectiveness of this new treatment in these young patients.

The study will involve administering patritumab deruxtecan to participants through an intravenous infusion, which means the medication is given directly into a vein. The trial will be conducted in two parts. In the first part, researchers will focus on understanding how safe the treatment is and determining the best dose to use. In the second part, they will look at how well the treatment works in controlling the cancer. Throughout the study, participants will be closely monitored for any side effects and to see how their cancer responds to the treatment.

In addition to patritumab deruxtecan, other medications may be used to help manage symptoms or side effects. These include dexamethasone, which is a type of steroid, and other medications that help prevent nausea and vomiting. The study aims to provide valuable information on the potential benefits and risks of using patritumab deruxtecan in treating these challenging pediatric cancers.

]]> Study of drug combinations including cisplatin, carboplatin, doxorubicin, fluorouracil, vincristine, etoposide, irinotecan, gemcitabine, oxaliplatin and sorafenib for children with hepatoblastoma or hepatocellular carcinoma https://clinicaltrials.eu/trial/study-on-hepatoblastoma-and-hepatocellular-carcinoma-in-children-using-cisplatin-and-drug-combinations/ Wed, 29 Apr 2026 15:03:27 +0000 https://clinicaltrials.eu/trial/study-on-hepatoblastoma-and-hepatocellular-carcinoma-in-children-using-cisplatin-and-drug-combinations/ This clinical trial is studying treatments for Hepatoblastoma and Hepatocellular Carcinoma, which are types of liver cancer. The study will test several chemotherapy medications including cisplatin, carboplatin, doxorubicin, fluorouracil, vincristine, etoposide, irinotecan, gemcitabine, oxaliplatin, and sorafenib.

The purpose of this study is to evaluate different treatment combinations for various risk groups of liver cancer patients. The treatments will be given through infusion into a vein or as tablets, depending on the specific medication. The study will compare different combinations of these medications to find out which ones work best for specific patient groups while monitoring side effects.

Patients will be divided into different groups based on their specific type of liver cancer and risk level. The study will track how well the cancer responds to treatment, how long patients remain free of cancer progression, and overall survival. Throughout the treatment, doctors will closely monitor patients’ heart, kidney, and hearing function, as some of these medications can affect these areas.

]]> Study on Doxorubicin, Fluorouracil, and Oxaliplatin for Children and Adolescents with Primary Malignant Liver Cancer https://clinicaltrials.eu/trial/study-on-doxorubicin-fluorouracil-and-oxaliplatin-for-children-and-adolescents-with-primary-malignant-liver-cancer/ Wed, 29 Apr 2026 14:58:12 +0000 https://clinicaltrials.eu/trial/study-on-doxorubicin-fluorouracil-and-oxaliplatin-for-children-and-adolescents-with-primary-malignant-liver-cancer/ This clinical trial focuses on children and adolescents with primary malignant liver cancer, specifically Hepatoblastoma and Hepatocarcinoma. The study aims to explore the possibility of tailoring treatment based on the stage of the disease, reducing side effects without affecting the cure rate, improving treatment effectiveness, and selecting the best surgical methods. The trial involves several medications, including Doxorubicin Hydrochloride, Fluorouracil, Oxaliplatin, Cisplatin, Sorafenib Tosilate, Irinotecan Hydrochloride, Etoposide, Gemcitabine Hydrochloride, Vinorelbine, Carboplatin, and Sodium Thiosulfate (known as Pedmark). These medications are used to treat cancer and are administered either intravenously or orally, depending on the specific drug.

The purpose of the study is to improve the treatment of liver cancer in young patients by classifying them into different groups based on the disease stage and testing various treatment methods. Participants will receive one or more of the mentioned medications, and some may receive a placebo. The study will monitor the effectiveness of these treatments over a period, aiming to enhance survival rates and reduce treatment-related side effects. The trial will also assess the surgical options available for treating these liver cancers.

Throughout the study, participants will be closely monitored to evaluate their response to the treatment and any side effects they may experience. The trial seeks to find the most effective treatment combinations and surgical approaches to improve outcomes for children and adolescents with these types of liver cancer. The study is expected to continue until 2027, with the goal of advancing the understanding and treatment of Hepatoblastoma and Hepatocarcinoma in young patients.

]]>